A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy
Xiaoniu Miao, Yi Luo, Xi Huang, Suki Man-Yan Lee, Zhijun Yuan, Yongzhou Tang, Liandi Chen, Chao Wang, Fan Wu, Yi-Feng Xu, Wenchao Jiang, Wei Gao, Xuedong Song, Yao Yan, Tuling Pang, Cheng Chen, Yuefeng Zou, Weihui Fu, Liping Wan, Javier Gilbert‐Jaramillo, Michael L. Knight, Tiong Kit Tan, Pramila Rijal, Alain Townsend, Joanne Sun, Xiaolin Liu, William James, Andy Tsun, Yingda Xu
Abstract
, inhibiting the interaction of recombinant S1 to ACE2 and transduction of ACE2-overexpressing cells by S-pseudotyped lentivirus with IC50s substantially below 100 pM, and with potency approximately 100-fold greater than ACE2-Fc itself. Moreover, 89C8-ACE2 was able to neutralize authentic viral infection in a standard 96-h co-incubation assay at low nanomolar concentrations, making this class of molecule a promising lead for therapeutic applications.